Berenberg Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $34
Portfolio Pulse from Benzinga Newsdesk
Berenberg analyst Andy Chen has initiated coverage on RAPT Therapeutics with a Buy rating and a price target of $34.
September 14, 2023 | 9:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Berenberg has initiated coverage on RAPT Therapeutics with a Buy rating and a price target of $34, which could positively impact the stock.
The initiation of coverage by Berenberg with a Buy rating indicates a positive outlook for RAPT Therapeutics. The price target of $34 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100